CRG PREMIERE

Serial Number 98747364
645

Registration Progress

Application Filed
Sep 12, 2024
Under Examination
Approved for Publication
Published for Opposition
Registered

Attorney Assistance

Final Refusal E-Mailed
Due: Feb 05, 2026 47 days

Trademark Image

CRG PREMIERE

Basic Information

Serial Number
98747364
Filing Date
September 12, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
645
Status Date
Nov 5, 2025
Application
Pending
Classes
036

Rights Holder

CR Group L.P.

13
Address
1000 Main Street
Suite 2500
Houston, TX 77002

Ownership History

CR Group L.P.

Original Applicant
13
Houston, TX

Legal Representation

Attorney
Shane Percival

USPTO Deadlines

Next Deadline
47 days remaining
Final Refusal E-Mailed
Due Date
February 05, 2026
Extension Available
Until May 05, 2026

Application History

14 events
Date Code Type Description Documents
Nov 5, 2025 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Nov 5, 2025 GNFR O FINAL REFUSAL E-MAILED Loading...
Nov 5, 2025 CNFR R FINAL REFUSAL WRITTEN Loading...
Sep 19, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 19, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 19, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 16, 2025 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Jun 16, 2025 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Mar 19, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 19, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Mar 19, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 13, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 27, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 12, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 036
Financial Services, namely, providing debt and equity financing to bio-pharmaceutical, biotechnology, healthcare, drug delivery, healthcare diagnostic, and medical device companies; Investment advisory services; Financial services, namely, providing structured financing for intellectual property assets, namely, revenue streams from patents, trademarks, and trade secrets; Financial services, namely, providing structured financing to ownership entities of intellectual property assets, namely, corporations, research institutions, and inventors; Financial services, namely, investment in intellectual property assets, namely, the licensing of, and purchasing an ownership interest in, revenue streams from patents, trademarks, and trade secrets; Financial services, namely, investment in assets protected by intellectual property, namely, the licensing of, and purchasing an ownership interest in, revenue streams from intellectual property protected assets; Financial services, namely, the formation and management of pool investment vehicles and investment accounts for the purpose of investment in debt and equity interests in bio-pharmaceutical companies, biotechnology companies, healthcare companies, drug delivery companies, healthcare diagnostic companies, medical device companies, and intellectual property assets, namely, revenue streams from patents, trademarks, and trade secrets.

Additional Information

Pseudo Mark
CR GROUP PREMIERE

Classification

International Classes
036